s. dazu hier.
US FDA approves Pfizer's maternal RSV vaccine to protect infants | Reuters
The U.S. Food and Drug Administration on Monday approved Pfizer's respiratory syncytial virus (RSV) vaccine for use in women during the middle of the third trimester of pregnancy to protect their babies.
Eine gewohnt exzellente Analyse der Problematik im Detail liefert wie so oft @TracyBethHoeg :
Sigh@US_FDA just approved Pfizer vax ABRYSVO in pregnancy to protect infants against RSV despite a 20%! higher rate of preterm birth in vax group (5.7%) vs controls (4.7%)
— Tracy Høeg, MD, PhD (@TracyBethHoeg) August 21, 2023
Most of VRBPAC shrugged off signal as "non significant" but study underpowered🧵https://t.co/UIGtm8t3aG pic.twitter.com/wdEHyv9Kay